Wegovy is a groundbreaking medication approved by the FDA to assist in weight loss for adults struggling with obesity and weight-related health conditions.
Wegovy contains semaglutide, a hormone that mimics GLP-1, which regulates appetite and food intake.
Clinical trials have demonstrated that Wegovy significantly aids in weight loss, with participants losing an average of 15% of their body weight over 68 weeks.
Wegovy is administered via a once-weekly injection. The dosage is gradually increased over 16 weeks to minimize potential side effects and enhance tolerance.
Wegovy is recommended for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition, such as hypertension or type 2 diabetes.
Beyond shedding pounds, Wegovy improves various health markers, including blood pressure, cholesterol levels, and blood sugar control.
Common side effects include nausea, diarrhea, vomiting, and constipation. Most side effects are mild to moderate and tend to diminish over time.
For optimal results, Wegovy should be used in conjunction with a reduced-calorie diet and increased physical activity, emphasizing a holistic approach to weight management.